Structure of aldehyde reductase in ternary complex with a 5-arylidene-2,4-thiazolidinedione aldose reductase inhibitor.

[1]  O. El-Kabbani,et al.  Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. , 2009, Bioorganic & medicinal chemistry.

[2]  O. El-Kabbani,et al.  Structure of aldehyde reductase in ternary complex with coenzyme and the potent 20alpha-hydroxysteroid dehydrogenase inhibitor 3,5-dichlorosalicylic acid: implications for inhibitor binding and selectivity. , 2008, Archives of biochemistry and biophysics.

[3]  K. Viswanath,et al.  Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy , 2008, Molecular vision.

[4]  O. El-Kabbani,et al.  Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors. , 2008, Bioorganic & medicinal chemistry.

[5]  Thierry Langer,et al.  Evaluation of in vitro aldose redutase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. , 2007, Bioorganic & medicinal chemistry letters.

[6]  D. Conklin,et al.  Aldehyde metabolism in the cardiovascular system. , 2007, Molecular bioSystems.

[7]  Carole L. Linster,et al.  Vitamin C , 2007, The FEBS journal.

[8]  James E. Bray,et al.  Enzymology and Molecular Biology of Carbonyl Metabolism , 2005 .

[9]  Connie Darmanin,et al.  Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. , 2005, Journal of medicinal chemistry.

[10]  A. Flyvbjerg,et al.  From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. , 2004, Endocrine reviews.

[11]  T. Tomizaki,et al.  Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with fidarestat and minalrestat: Implications for the binding of cyclic imide inhibitors , 2004, Proteins.

[12]  J. Petrash.  All in the family: aldose reductase and closely related aldo-keto reductases , 2004, Cellular and Molecular Life Sciences CMLS.

[13]  O. El-Kabbani,et al.  Structure of human aldose reductase holoenzyme in complex with Statil: An approach to structure‐based inhibitor design of the enzyme , 2002, Proteins.

[14]  Peter Kuhn,et al.  Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. , 2002, Journal of synchrotron radiation.

[15]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[16]  O. El-Kabbani,et al.  Modelling studies of the active site of human sorbitol dehydrogenase: an approach to structure-based inhibitor design of the enzyme. , 2001, Bioorganic & medicinal chemistry letters.

[17]  J. Shaw,et al.  Global and societal implications of the diabetes epidemic , 2001, Nature.

[18]  O. El-Kabbani,et al.  Aldose and aldehyde reductases: Correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site , 2000, Proteins.

[19]  O. El-Kabbani,et al.  Modelling studies on the binding of substrate and inhibitor to the active site of human sorbitol dehydrogenase. , 2000, Bioorganic & medicinal chemistry letters.

[20]  S. Old,et al.  Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites. , 1999, Molecular vision.

[21]  O. El-Kabbani,et al.  Studies on the inhibitor‐binding site of porcine aldehyde reductase: Crystal structure of the holoenzyme‐inhibitor ternary complex , 1997, Proteins.

[22]  D. Moras,et al.  A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. , 1997, Structure.

[23]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[24]  M. Foppiano,et al.  Worldwide pharmacovigilance systems and tolrestat withdrawal , 1997, The Lancet.

[25]  A. Hara,et al.  Aldose reductase is a major reductase for isocaproaldehyde, a product of side-chain cleavage of cholesterol, in human and animal adrenal glands. , 1996, Archives of biochemistry and biophysics.

[26]  Sookja K. Chung,et al.  Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[28]  G. Petsko,et al.  An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose 6-phosphate. , 1994, Biochemistry.

[29]  G. Petsko,et al.  Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme. , 1994, Biochemistry.

[30]  P. Barth,et al.  Sequence of pig lens aldose reductase and electrospray mass spectrometry of non-covalent and covalent complexes. , 1993, European journal of biochemistry.

[31]  Wolfgang Kabsch,et al.  Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants , 1993 .

[32]  F A Quiocho,et al.  Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Taniguchi Naoyuki,et al.  Identity of a major 3-deoxyglucosone-reducing enzyme with aldehyde reductase in rat liver established by amino acid sequencing and cDNA expression , 1993 .

[34]  S. Narayanan.  Aldose reductase and its inhibition in the control of diabetic complications. , 1993, Annals of clinical and laboratory science.

[35]  W. Zimmer,et al.  Molecular cloning of testicular 20 alpha-hydroxysteroid dehydrogenase: identity with aldose reductase. , 1993, Biochemistry.

[36]  F A Quiocho,et al.  An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. , 1992, Science.

[37]  D. Moras,et al.  Novel NADPH-binding domain revealed by the crystal structure of aldose reductase , 1992, Nature.

[38]  T. Nakayama,et al.  Aldehyde reductase is a major protein associated with 3-deoxyglucosone reductase activity in rat, pig and human livers. , 1991, The Biochemical journal.

[39]  S. Srivastava,et al.  Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors. , 1990, Biochemical pharmacology.

[40]  B. Wermuth,et al.  The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. , 1989, The Journal of biological chemistry.

[41]  T. Flynn,et al.  Aldose reductase from human psoas muscle. Purification, substrate specificity, immunological characterization, and effect of drugs and inhibitors. , 1989, The Journal of biological chemistry.

[42]  T. Nakayama,et al.  Reductases for carbonyl compounds in human liver. , 1986, Biochemical pharmacology.

[43]  B. Wermuth,et al.  Aldose and aldehyde reductase exhibit isocorticosteroid reductase activity. , 1983, European journal of biochemistry.

[44]  G. Branlant.  Properties of an aldose reductase from pig lens. Comparative studies of an aldehyde reductase from pig lens. , 1982, European journal of biochemistry.

[45]  B. Wermuth,et al.  Purification and characterization of human-brain aldose reductase. , 1982, European journal of biochemistry.

[46]  T. Flynn.  Aldehyde reductases: monomeric NADPH-dependent oxidoreductases with multifunctional potential. , 1982, Biochemical pharmacology.

[47]  G. Branlant,et al.  Purification and Some Properties of Aldehyde Rcductases from Pig Liver , 1980 .

[48]  B. Wermuth,et al.  Purification and properties of NADPH-dependent aldehyde reductase from human liver. , 1977, The Journal of biological chemistry.

[49]  D. Tulsiani,et al.  Resolution and partial characterization of two aldehyde reductases of mammalian liver. , 1977, The Journal of biological chemistry.

[50]  T. Flynn,et al.  Properties of the nicotinamide adenine dinucleotide phosphate-dependent aldehyde reductase from pig kidney. Amino acid composition, reactivity of cysteinyl residues, and stereochemistry of D-glyceraldehyde reduction. , 1975, The Journal of biological chemistry.

[51]  B. Matthews.  Solvent content of protein crystals. , 1968, Journal of molecular biology.

[52]  P. Oates.  Aldose reductase, still a compelling target for diabetic neuropathy. , 2008, Current drug targets.

[53]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[54]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[55]  P. Oates.  Polyol pathway and diabetic peripheral neuropathy. , 2002, International review of neurobiology.

[56]  O. El-Kabbani,et al.  Structure and mechanism of aldehyde reductase. , 1995, Advances in experimental medicine and biology.

[57]  Alexander McPherson,et al.  [5]Crystallization of macromolecules: General principles , 1985 .